Navigation Links
INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research with Seed Round Investment in Sanguine BioSciences
Date:2/21/2013

VALENCIA, Calif., Feb. 21, 2013 /PRNewswire/ -- SANGUINE BIOSCIENCES, INC. ("Sanguine"), a biotechnology company empowering patients in biomedical research, has announced the closing of its seed financing round, led by INVENT Ventures and Heliant Ventures.

Sanguine engages research subjects through social media and non-profit advocacy, and schedules blood draws, which are then processed into DNA, RNA, cells, plasma, and serum, to be used as biomedical research materials at pharmaceutical companies and research institutions. The company has developed the infrastructure to provide research subjects with information on how their samples were used, in order to ultimately increase trust and information flow back to researchers.

"Sanguine has experienced significant growth since Q4 2012, both in terms of revenues and number of research subjects. The successful completion of the laboratory and regulatory infrastructure allowed us the opportunity to open our doors to research participants, both healthy, and diagnosed with an ailment(s), and to researchers at numerous pharmaceutical companies and academic institutions.

We plan to use the funds raised in the seed round to further develop our internal infrastructure in order to safely and efficiently collect, process, document, and store up to 1,000 blood samples each month across the west coast. We are looking forward to scaling up and providing researchers with the samples they need to perform their investigations, while also providing patients with the knowledge of how their samples have impacted Personalized Medicine research."Brian Neman , CEO

"Sanguine is building products and processes that will revolutionize personalized medicine research," said INVENT CEO Bryce Knight . "We are thrilled to support Sanguine and its exceptional team through their growth at the forefront of multiple rapidly-growing markets." 

"We are very happy to jointly lead this round of investment and to be connected to a company at the forefront of its industry. Sanguine's business model achieves that unique harmony between placing the patient interests first while still generating returns for all its stakeholders," said Heliant Ventures Director Ben Weiss . "Full credit to the hard-working Sanguine team for reaching this important milestone and we look forward to supporting the company to realize its exciting growth potential."

About Sanguine BioSciences Inc.
Sanguine BioSciences is a biotechnology company bridging the gap between patients and researchers by providing transparency throughout the personalized medicine R&D process. Sanguine collects and de-identifies patient-derived data in the form of biospecimen and physician and self-reported information. These data are generated and then made available to researchers involved in drug and biomarker research and discovery. (http://sanguinebio.com)

About INVENT Ventures
INVENT Ventures Inc. (OTC: IDEA) is a publicly traded venture fund that builds and invests in transformative technology businesses. INVENT primarily operates in markets of digital media, consumer Internet, and social networking, and has built six companies at various stages of development. (www.invent.vc.)

About Heliant Ventures
Established in 2012, Heliant Ventures is a venture capital fund backed by leading investors across Asia and Australia. (www.heliantventures.com)


'/>"/>
SOURCE Sanguine BioSciences, Inc.; INVENT Ventures, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Researchers invent acoustic-assisted magnetic information storage
2. Cellphone Microscope Inventor Honored with Biophotonics Technology Innovator Award
3. Cieri Media Announces New Science Series 'Bright Ideas' Focusing on Latest Inventions
4. NTUs sense-ational invention helps underwater vessels navigate with ease
5. Collegiate Inventors Honored for Innovative Science and Technology Advances
6. Gevo Doesnt Infringe Butamaxs 017 Patent; Gevo was First to Invent Enzyme in 017 Patent; Gevo has Advanced Beyond That and Now Uses Different Enzymes
7. PharmaVOICE Names Four inVentiv Health Associates Among "100 Most Inspiring" Leaders in Healthcare
8. University of Utah physicists invent spintronic LED
9. RURO Adds Critical Level Monitoring Functionality to its Inventory Management Software FreezerPro.
10. Ocean Tomo Study Ranks Top 25 Most Inventive Illinois Companies in 2011 for Crain’s Chicago Business
11. College Chairman And Prolific Inventor Develops Life-Saving, Real-Time Diagnostic Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Ca (PRWEB) , ... January 18, 2017 , ... ... events for tech innovators, engineers, and scientists from around the world, was today ... News. The awards program is based entirely on merit and decided upon by ...
(Date:1/19/2017)... BETHESDA, Md. , Jan. 18, 2017  Northwest ... company developing DCVax® personalized immune therapies for operable and ... Marnix Bosch , Chief Technical Officer of NW Bio, ... Thursday, January 19, 2017, at the Hyatt Regency Hotel ... Dr. Bosch will chair the session entitled "New Therapeutic ...
(Date:1/18/2017)... According to a new market research report "In situ Hybridization Market ... User (Molecular Diagnostic Laboratories, Academic and Research Institutions) - Global Forecast to 2021" ... 2021 from USD 557.1 Million in 2016, growing at a CAGR of 5.8%. ... ... MarketsandMarkets Logo ...
(Date:1/18/2017)... ... 18, 2017 , ... Executive search firm Slone Partners proudly ... to the advancement of the clinical trials segment. Hosted in Miami, this conference ... planning and management. , As executive talent specialists in the industries central ...
Breaking Biology Technology:
(Date:12/22/2016)... YORK , December 22, 2016 ... provider of secure solutions for the e-Government, Public Safety, HealthCare, and ... subsidiary of SuperCom, has been selected to implement and deploy a ... in Northern California , further expanding its presence ... ...
(Date:12/16/2016)... , Dec. 16, 2016   IdentyTechSolutions ... Identity management products and solutions and a cutting-edge ... today that it is offering seamless, integrated solutions ... security entrance products. The solutions provide IdentyTech,s customers ... secure their facilities from crime and theft. ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
Breaking Biology News(10 mins):